A leading global device company MicroPort announces its entry Into the India market with its flagship technology FIREHAWKTES (Target Eluting Stent)
New Delhi, March 02, 2017: MicroPort Scientific Corporation (“MPSC”) (HK: 853), a leading global medical technology company dedicated to the innovation, manufacturing and marketing of high-end medical devices, today announced the commencement of its Indian operations. The Indian arm MicroPort Scientific India Pvt. Ltd., a wholly owned subsidiary of MPSC, is aimed to serve the Indian patients with high-quality and yet affordable medical solutions to save, reshape and improve their quality of their life.
Cardiovascular diseases, especially coronary heart disease (CHD), are epidemic in India. The Registrar General of India reported that CHD led to 17% of total deaths and 26% of adult deaths in 2001-2003, which increased to 23% of total and 32% of adult deaths in 2010-2013.
“India has the third largest coronary angioplasties cases in the world, and the market has been experiencing rapid growth in recent years due to better access lead by Indian government’s initiative of providing universal health coverage. The establishment of the Indian subsidiary marks another solid step forward in strengthening the global presence of MPSC,” said Mr. Jonathan Chen, Senior Vice President of International Operations and Investor Relations. “MicroPort is becoming a major global player in the global medical device industry. We are dedicated to the ideology of ‘The Patient Always Comes First’ and with the launch of Firehawk TES by our Indian subsidiary, we hope to offer better solutions of interventional therapies for the Indian market, and bring patients a whole generation of affordable medical technologies to improve the lives for Indian patients,” Mr. Chen added.
MicroPort Scientific Corporation, founded in 1998 and headquartered in Shanghai, China,has become a premier medical solution provider covering 10 major medical disciplines including interventional cardiology, orthopedics, endovascular, neurovasular, electrophysiology, diabetes and endocrine management, surgical management and others. With its products currently approved for use in over 5,000 hospitals in 80 countries worldwide, MicroPort® Scientific is contributing to a better world through its life-saving medical therapies and quality-improving care devices being used in patients every 15 seconds. MicroPort has also been active in expanding its business globally through acquisitions, joint ventures and investment transactions in its core strategic markets.
Mr.Riyaz Desai, Managing Director India, commented “We see this as a new beginning in the Indian healthcare space. Indian government is committed to not only providing universal health coverage but focused on delivering equitable high quality healthcare to all the classes. MicroPort is well poised in aligning with government as well as medical professionals in delivering the “best in class” technologies at an affordable price. This will have a profound impact on Indian patient outcomes. It is not just about being able to access a range of innovative products with a proven track record like our breakthrough TES (Target Eluting Stent) called FIREHAWK to treat coronary artery disease. Indian healthcare can also leverage on MicroPort’s vast investment and experience in research and development (R&D) in high-quality medical technology. This marks the start of a new chapter in the history of the Indian MedTech industry, as this dynamic and promising Indian market has been showing a paradigm shift in its healthcare delivery mechanism. We are here not only at an opportune time, but I genuinely feel that Indian medical ecosystem is maturing and forcing manufacturers to provide the best in class medical care at affordable prices We are well positioned as MicroPort to deliver for the Indian market and proud to be part of history in making as far as patient care in India is concerned.”
MicroPort’s India entry coincides with 8th edition of INDIA LIVE, country’s biggest and most respectable international educational event by Interventional Cardiology Foundation of India (IFCI) which begins on 1st March 2017 in New Delhi. MicroPort will have a significant presence at the INDIA LIVE 2017.
Corporate Comm India(CCI Newswire)
